Compare ADEA & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADEA | DYN |
|---|---|---|
| Founded | 1990 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2020 | 2020 |
| Metric | ADEA | DYN |
|---|---|---|
| Price | $12.84 | $15.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | ★ $38.25 | $34.33 |
| AVG Volume (30 Days) | 1.5M | ★ 2.2M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $443,386,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.99 | N/A |
| P/E Ratio | $39.05 | ★ N/A |
| Revenue Growth | ★ 17.91 | N/A |
| 52 Week Low | $11.93 | $14.00 |
| 52 Week High | $34.34 | $27.31 |
| Indicator | ADEA | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 24.07 | 38.49 |
| Support Level | N/A | $14.43 |
| Resistance Level | $26.48 | $19.48 |
| Average True Range (ATR) | 0.94 | 0.96 |
| MACD | -0.19 | -0.21 |
| Stochastic Oscillator | 0.70 | 0.56 |
Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.